Variation within the PPARG gene is associated with residual beta-cell function and glycemic control in children and adolescents during the first year of clinical type 1 diabetes

Pediatric Diabetes

Volumn 9, Issue 4 PART 1, 2008, Pages 297-302

  Pörksen, Sven ^a,b   Nielsen, Lotte B ^a   Mortensen, Henrik B ^a   Danne, Thomas ^c   Kocova, Mirjana ^d   Castaño, Luis ^e   Pociot, Flemming ^f   Hougaard, Philip ^g   Ekstrøm, Claus T ^h   Gammeltoft, Steen ^a   Knip, Mikael ⁱ   Hansen, Lars ^b  

^a GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^b NOVO NORDISK A S   (Denmark)

^c Kinderkrankenhaus auf der Bult ^*  (Germany)

^d SS CYRIL AND METHODIUS UNIVERSITY   (Macedonia)

^e HOSPITAL DE CRUCES   (Spain)

^f STENO DIABETES CENTER   (Denmark)

^g UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^h UNIVERSITY OF COPENHAGEN   (Denmark)

ⁱ UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Children; Disease progression; Glycemic control; Haplotype; PPARgamma; Pro12 Ala; Residual b cell function; Type 1 diabetes

Indexed keywords

C PEPTIDE; HEMOGLOBIN A1C; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADOLESCENT; ARTICLE; CELL FUNCTION; CELL STIMULATION; CHILD; CONTROLLED STUDY; DISEASE COURSE; EVENING DOSAGE; FEMALE; FOLLOW UP; FOOD INTAKE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GLYCEMIC CONTROL; HAPLOTYPE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; BLOOD GLUCOSE; CHILD; DIABETES MELLITUS, TYPE 1; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INSULIN-SECRETING CELLS; MALE; PPAR GAMMA; TIME FACTORS;

EID: 48649105294     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/j.1399-5448.2008.00398.x     Document Type: Article

References (18)

1. Pociot F, McDermott MF. Genetics of type 1 diabetes mellitus. Genes Immun 2002: 3: 235-249.
2. Eftychi C, Howson JM, Barratt BJ et al. Analysis of the type 2 diabetes-associated single nucleotide polymorphisms in the genes IRS1, KCNJ11, and PPARG2 in type 1 diabetes. Diabetes 2004: 53: 870-873.
3. Johansen A, Jensen DP, Bergholdt R et al. IRS1, KCNJ11, PPARgamma2 and HNF-1alpha: Do amino acid polymorphisms in these candidate genes support a shared aetiology between type 1 and type 2 diabetes? Diabetes Obes Metab 2006: 8: 75-82.
4. Altshuler D, Hirschhorn JN, Klannemark M et al. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000: 26: 76-80.
5. Todd JA, Walker NM, Cooper JD et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet 2007: 39: 857-864.
6. Hakonarson H, Grant SF, Bradfield JP et al. A genome-wide association study identifies KIAA0350 as a type 1 diabetes gene. Nature 2007: 448: 591-594.
7. The DCCT Research Group. Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual beta-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). J Clin Endocrinol Metab 1987: 65: 30-36.
8. Hansen L, Ekstrom CT, Tabanera Y Palacios R, Anant M, Wassermann K, Reinhardt RR. The Pro12Ala variant of the PPARG gene is a risk factor for peroxisome proliferator-activated receptor-gamma/alpha agonist-induced edema in type 2 diabetic patients. J Clin Endocrinol Metab 2006: 91: 3446-3450.
9. Nielsen LB, Mortensen HB, Chiarelli F et al. Impact of IDDM2 on disease pathogenesis and progression in children with newly diagnosed type 1 diabetes: Reduced insulin antibody titres and preserved beta cell function. Diabetologia 2006: 49: 71-74.
10. Kukko M, Kimpimäki T, Korhonen S et al. Dynamics of diabetes-associated autoantibodies in young children with human leukocyte antigen-conferred risk for type 1 diabetes recruited from the general population. J Clin Endocrinol Metab 2005: 90: 2712-2717.
11. Ek J, Andersen G, Urhammer SA et al. Studies of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 (PPAR-gamma2) gene in relation to insulin sensitivity among glucose tolerant Caucasians. Diabetologia 2001: 44: 1170-1176.
12. Deeb SS, Fajas L, Nemoto M et al. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998: 20: 284-287.
13. Doney AS, Fischer B, Cecil JE et al. Association of the Pro12Ala and C1431T variants of PPARG and their haplotypes with susceptibility to Type 2 diabetes. Diabetologia 2004: 47: 555-558.
14. Jaziri R, Lobbens S, Aubert R et al. The PPARG Pro12Ala polymorphism is associated with a decreased risk of developing hyperglycemia over 6 years and combines with the effect of the APM1 G-11391A single nucleotide polymorphism: The Data From an Epidemiological Study on the Insulin Resistance Syndrome (DESIR) study. Diabetes 2006: 55: 1157-1162.
15. Vaccaro O, Lapice E, Monticelli A et al. Pro12Ala polymorphism of the PPARgamma2 locus modulates the relationship between energy intake and body weight in type 2 diabetic patients. Diabetes Care 2007: 30: 1156-1161.
16. Stumvoll M, Haring H. The peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism. Diabetes 2002: 51: 2341-2347.
17. Gupta D, Peshavaria M, Jetton TL, Leahy JL. Transcriptional regulation of GIP receptor by PPAR gamma in islet beta cells. ADA Scientific Sessions 2007: 1701-P (Abstract): 56: A431.
18. Bell DS. Beta-cell rejuvenation with thiazolidinediones. Am J Med 2003: 115 (Suppl. 8A): 20S-23S.